Contineum Therapeutics, Inc. (CTNM) has been able to do well to advance the use of an LPA1R antagonist for the treatment of neuroinflammatory disorders in a phase 1 healthy volunteer study. Why ...
For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major ...
ST316 interfered with β-catenin immune-exclusion allowing for stronger cytotoxic T-cell activity. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ST316 for the treatment ...
Explore the role of depression drugs targeting the neurokinin-1 receptor and their potential impact on major depressive ...
Researchers report that redesigning neurokinin-1 receptor (NK1R) antagonists can restore antidepressant-like effects in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results